↓ Skip to main content

Dove Medical Press

Article Metrics

MicroRNA-205 downregulates mixed-lineage-AF4 oncogene expression in acute lymphoblastic leukemia

Overview of attention for article published in OncoTargets and therapy, August 2013
Altmetric Badge

Mentioned by

facebook
1 Facebook page

Citations

dimensions_citation
7 Dimensions

Readers on

mendeley
14 Mendeley
Title
MicroRNA-205 downregulates mixed-lineage-AF4 oncogene expression in acute lymphoblastic leukemia
Published in
OncoTargets and therapy, August 2013
DOI 10.2147/ott.s45376
Pubmed ID
Authors

Liping, Jingxin, Yonghui, Xiaoning, Dehua, Li, Lili, Li, Chengwang Xu

Abstract

Myeloid/lymphoid or mixed-lineage AF4 acute lymphoblastic leukemia (MLL-AF4 ALL) is a pediatric leukemia that occurs rarely in adults. MLL-AF4 ALL is typically characterized by the presence of chromosomal translocation (t(4;1l)(q21;q23)), leading to expression of MLL-AF4 fusion protein. Although MLL-AF4 fusion protein triggers a molecular pathogenesis and hematological presentations that are unique to leukemias, the precise role of this oncogene in leukemogenesis remains unclear. Previous studies have indicated that microRNAs (miRs) might modulate the expression of MLL-AF4 ALL fusion protein, thereby suggesting the involvement of miR in progression or suppression of MLL-AF4 ALL. We have previously demonstrated that miR-205 negatively regulates transcription of an MLL-AF4 luciferase reporter. Here, we report that exogenous expression of miR-205 in MLL-AF4 human cell lines (RS4;11 and MV4-11) inversely regulates the expression of MLL-AF4 at both messenger RNA (mRNA) and protein level. Furthermore, miR-205 significantly induced apoptosis in MLL-AF4 cells as evidenced by Annex in V staining using fluorescence-activated cell sorting (FACS) analysis. The proliferative capacity of leukemic cells was suppressed by miR-205. The addition of an miR-205 inhibitor was able to restore the observed effects. In conclusion, these findings demonstrate that miR-205 may have potential value as a novel therapeutic agent in the treatment of MLL-AF4 ALL.

Mendeley readers

The data shown below were compiled from readership statistics for 14 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 14 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 5 36%
Researcher 3 21%
Student > Doctoral Student 1 7%
Student > Postgraduate 1 7%
Unknown 4 29%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 4 29%
Medicine and Dentistry 2 14%
Agricultural and Biological Sciences 2 14%
Environmental Science 1 7%
Unknown 5 36%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 December 2013.
All research outputs
#2,902,981
of 3,617,832 outputs
Outputs from OncoTargets and therapy
#193
of 249 outputs
Outputs of similar age
#88,364
of 112,588 outputs
Outputs of similar age from OncoTargets and therapy
#20
of 33 outputs
Altmetric has tracked 3,617,832 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 249 research outputs from this source. They receive a mean Attention Score of 1.7. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 112,588 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 33 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.